Your browser doesn't support javascript.
loading
A Pan-Cancer Analysis of the Oncogenic Role of Cell Division Cycle-Associated Protein 4 (CDCA4) in Human Tumors.
Fang, Hui; Sheng, Shuyan; Chen, Bangjie; Wang, Jianpeng; Mao, Deshen; Han, Yanxun; Liu, Yuchen; Wang, Xinyi; Gui, Siyu; Zhang, Tongyuan; Zhang, Lizhi; Li, Conghan; Hu, Xinyang; Deng, Wanyu; Liu, Xin; Xu, Honghai; Xu, Wentao; Wang, Xingyu; Liu, Rongqiang; Kong, Weihao.
Afiliação
  • Fang H; Department of Pharmacy, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China.
  • Sheng S; The First Clinical Medical College of Anhui Medical University, Hefei, China.
  • Chen B; The First Clinical Medical College of Anhui Medical University, Hefei, China.
  • Wang J; Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Mao D; The First Clinical Medical College of Anhui Medical University, Hefei, China.
  • Han Y; The First Clinical Medical College of Anhui Medical University, Hefei, China.
  • Liu Y; Department of Otolaryngology Head and Neck surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Wang X; Department of Otolaryngology Head and Neck surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Gui S; The First Clinical Medical College of Anhui Medical University, Hefei, China.
  • Zhang T; Department of Ophthalmology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Zhang L; Department of Emergency Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Li C; The First Clinical Medical College of Anhui Medical University, Hefei, China.
  • Hu X; The First Clinical Medical College of Anhui Medical University, Hefei, China.
  • Deng W; The First Clinical Medical College of Anhui Medical University, Hefei, China.
  • Liu X; The First Clinical Medical College of Anhui Medical University, Hefei, China.
  • Xu H; School of Pharmacy, Anhui Medical University, Hefei, China.
  • Xu W; Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Wang X; Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Liu R; Department of Emergency Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Kong W; Department of Hepatobiliary Surgery, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Front Immunol ; 13: 826337, 2022.
Article em En | MEDLINE | ID: mdl-35251007
ABSTRACT

PURPOSE:

To unravel the oncogenic role of CDCA4 in different cancers from the perspective of tumor immunity.

METHODS:

Raw data on CDCA4 expression in tumor samples and paracancerous samples were obtained from TCGA and GTEX databases. In addition, we investigated pathological stages and the survival analysis of CDCA4 in pan-cancer across Gene Expression Profiling Interactive Analysis (GEPIA) database. Cox Proportional Hazards Model shows that high CDCA4 levels are associated with several vital indicators in oncology. On the one hand, we explored the correlation between CADA4 expression and tumor immune infiltration by the TIMER tool; On the other hand, we utilized the methods of CIBERSORT and ESTIMATE computational to evaluate the proportion of tumor infiltrating immune cells (TIIC) and the amounts of stromal and immune components based on TCGA database. The use of antineoplastic drugs and the expression of CDCA4 also showed a high correlation via linear regression. Protein-Protein Interaction analysis was performed in the GeneMANIA database, and enrichment analysis was performed and predicted signaling pathways were identified by using Gene Ontology and Kyoto Encyclopedia of Genes. The correlation between CDCA4 expression with Copy number variations (CNV) and methylation is detailed, respectively. Molecular biology experiments including Western blotting, flow cytometry, EDU staining, Transwell and Wound Healing assay to validate the cancer promoting role of CDCA4 in hepatocellular carcinoma (HCC).

RESULTS:

Most tumors highly expressed CDCA4. Elevated CDCA4 expression was associated with poor OS and DFS. There was a significant correlation between CDCA4 expression and TITCs. Moreover, markers of TIICs exhibited distinct patterns of CDCA4 associated immune infiltration. In addition, we pay attention to the association between the expression of CDCA4 and the use of the anti-tumor drugs. CDCA4 is related to biological progress (BP), cellular component (CC) and molecular function (MF). Dopaminergic Synapse, AMPK, Sphingolipid, Chagas Disease, mRNA Surveillance were significantly enriched pathways in positive and negative correlation genes with CDCA4. CNV is thought to be a positive correlation with CDCA4 expression. Conversely, methylation is negative correlation with CDCA4 expression. Molecular biology experiments confirm a cancer promoting role for CDCA4 in HCC.

CONCLUSION:

CDCA4 may serve as a biomarker for cancer immunologic infiltration and poor prognosis, providing a new way of thinking for cancer treatment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article